Determination of Apixaban Levels in Human Plasma by a High-Throughput Liquid Chromatographic Tandem Mass Spectrometry Assay / Determinarea rapidă a apixabanului în plasma umană prin cromatografie de lichide de înaltă performanță cuplată cu spectrometrie de masă în tandem

1. Nutescu E. Apixaban: a novel oral inhibitor of factor Xa. Am J Health Syst Pharm. 2012;69(13):1113-26. DOI: 10.2146/ajhp11041810.2146/ajhp11041822722590Search in Google Scholar

2. Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013;52(2):69-82. DOI: 10.1007/s40262-012-0030-910.1007/s40262-012-0030-923292752Search in Google Scholar

3. European Medicine Agency, Eliquis: Summary of Product Characteristics. Available at http://www.ema.\europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed October 23rd, 2014.Search in Google Scholar

4. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. DOI: 10.1056/NEJMoa130250710.1056/NEJMoa130250723808982Search in Google Scholar

5. Cheng JW, Barillari G. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. J Clin Pharm Ther. 2014;39(2):118-35. DOI: 10.1111/jcpt.1212210.1111/jcpt.1212224383983Search in Google Scholar

6. Bruins Slot KM, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev. 2013 Aug 8;8:CD008980. DOI: 10.1002/14651858.CD008980.pub210.1002/14651858.CD008980.pub223925867Search in Google Scholar

7. Bauer KA. Pros and cons of new oral anticoagulants. Management of Thromboembolic Disease. Hematology Am Soc Hematol Educ Program. 2013;2013:464-70. DOI: 10.1182/asheducation-2013.1.46410.1182/asheducation-2013.1.46424319220Search in Google Scholar

8. Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting. Anesthesiology. 2013 Jun;118(6):1466-74. DOI: 10.1097/ ALN.0b013e318289bcba10.1097/ALN.0b013e318289bcba23416382Search in Google Scholar

9. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM. Regional anesthesia and antithrombotic agents: recommendations of the European society of Anaesthesiology. Eur J Anaesthesiol. 2010 Dec;27(12):999-1015. DOI: 10.1097/ EJA.0b013e32833f6f6f10.1097/EJA.0b013e32833f6f6f20890208Search in Google Scholar

10. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013 Feb;75(2):476-87. DOI: 10.1111/j.1365-2125.2012.04369.x10.1111/j.1365-2125.2012.04369.x355879822759198Search in Google Scholar

11. Bauer KA. Pros and cons of new oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2013;2013:464-70. DOI: 10.1182/asheducation-2013.1.46410.1182/asheducation-2013.1.464Search in Google Scholar

12. Brieger D. Anticoagulation: a GP primer on the new oral anticoagulants. Aust Fam Physician. 2014;43(5):254-9.Search in Google Scholar

13. Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. [Abstract] Thromb Haemost. 2013;110(2):283-94. DOI: 10.1160/ TH12-12-089810.1160/TH12-12-089823765180Search in Google Scholar

14. Vílchez JA, Gallego P, Lip GYH. Safety of new oral anticoagulant drugs: a perspective. Ther Adv Drug Saf 2014;5(1):8-20. DOI: 10.1177/204209861350794510.1177/2042098613507945411087525083259Search in Google Scholar

15. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, et al. Management of major bleeding complications and emergency surgery in patients on longterm treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis. 2013;106(6-7):382-93. DOI: 10.1016/j.acvd.2013.04.00910.1016/j.acvd.2013.04.00923810130Search in Google Scholar

16. Dincq AS, Lessire S, Douxfils J, Dogné JM, Gourdin M, Mullier F. Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting. Biomed Res Int. 2014;2014:385014. DOI: 10.1155/2014/38501410.1155/2014/385014416802725276784Search in Google Scholar

17. Eby C. Novel anticoagulants and laboratory testing. Int J Lab Hematol. 2013 Jun;35(3):262-8. DOI: 10.1111/ ijlh.1206510.1111/ijlh.1206523590653Search in Google Scholar

18. Gous T, Couchman L, Patel JP, Paradzai C, Arya R, Flanagan RJ. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit. 2014 Oct;36(5):597-605. DOI: 10.1097/ FTD.000000000000005910.1097/FTD.000000000000005924695356Search in Google Scholar

19. Korostelev M, Bihan K, Ferreol L, Tissot N, Hulot JS, Funck-Brentano C, et al. Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2014 Nov;100:230-5. DOI: 10.1016/j.jpba.2014.08.01110.1016/j.jpba.2014.08.01125173108Search in Google Scholar

20. Schmitz EM, Boonen K, van den Heuvel DJ, van Dongen JL, Schellings MW, Emmen JM, et al. Determination of dabigatran, rivaroxaban and apixaban by ultra- performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost. 2014 Oct;12(10):1636-46. DOI: 10.1111/jth.1270210.1111/jth.1270225142183Search in Google Scholar

21. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009 Jan;37(1):74-81. DOI: 10.1124/ dmd.108.02314310.1124/dmd.108.02314318832478Search in Google Scholar

22. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013 Nov;76(5):776-86. DOI: 10.1111/bcp.1210610.1111/bcp.12106385353623451769Search in Google Scholar

23. Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, et al. Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clin Pharmacol. 2013 Dec 6;5:177-84. DOI: 10.2147/CPAA.S5198110.2147/CPAA.S51981386136224353445Search in Google Scholar

24. Delavenne X, Mismetti P, Basset T. Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: application to pharmacokinetic study. J Pharm Biomed Anal. 2013 May 5;78-79:150-3. DOI: 10.1016/j. jpba.2013.02.007Search in Google Scholar

25. Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013 Dec;76(6):908-16. DOI: 10.1111/ bcp.1211410.1111/bcp.12114384531423488672Search in Google Scholar

26. Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 2014 Apr;14(2):147-54. DOI: 10.1007/ s40256-013-0055-y10.1007/s40256-013-0055-y396162824277644Search in Google Scholar

27. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost. 2014 Feb;111(2):240-8. DOI: 10.1160/TH13-06-047010.1160/TH13-06-047024172843Search in Google Scholar

28. Guidance for Industry, Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration. Federal Register. 2001;66.Search in Google Scholar

29. Guidance on the Investigation of Bioavailability and Bioequivalence. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products. 2001; CPMP/EWP/QWP/1401/98.Search in Google Scholar

30. Imre S, Vlase L, Muntean DL. Bioanalytical method validation. Rev Romana Med Lab. 2008;10(1):13-21.Search in Google Scholar

31. Guideline on bioanalytical method validation. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). 275542 / 2014. http:// www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdfSearch in Google Scholar

32. Guidance for Industry. Bioanalytical Method Validation. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Veterinary Medicine (CVM). September 2013 http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm368107.pdf Search in Google Scholar